Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes

Mirja Thomsen, Katrin Marth, Sebastian Loens, Judith Everding, Johanna Junker, Friederike Borngräber, Fabian Ott, Silvia Jesús, Mathias Gelderblom, Thorsten Odorfer, Gregor Kuhlenbäumer, Han-Joon Kim, Eva Schaeffer, Jos Becktepe, Meike Kasten, Norbert Brüggemann, Robert Pfister, Katja Kollewe, Joachim K Krauss, Ebba LohmannFrauke Hinrichs, Daniela Berg, Beomseok Jeon, Hauke Busch, Eckart Altenmüller, Pablo Mir, Christoph Kamm, Jens Volkmann, Simone Zittel, Andreas Ferbert, Kirsten E Zeuner, Arndt Rolfs, Peter Bauer, Andrea A Kühn, Tobias Bäumer, Christine Klein, Katja Lohmann

Abstract

BACKGROUND: Pathogenic variants in several genes have been linked to genetic forms of isolated or combined dystonia. The phenotypic and genetic spectrum and the frequency of pathogenic variants in these genes have not yet been fully elucidated, neither in patients with dystonia nor with other, sometimes co-occurring movement disorders such as Parkinson's disease (PD).

OBJECTIVES: To screen >2000 patients with dystonia or PD for rare variants in known dystonia-causing genes.

METHODS: We screened 1207 dystonia patients from Germany (DysTract consortium), Spain, and South Korea, and 1036 PD patients from Germany for pathogenic variants using a next-generation sequencing gene panel. The impact on DNA methylation of KMT2B variants was evaluated by analyzing the gene's characteristic episignature.

RESULTS: We identified 171 carriers (109 with dystonia [9.0%]; 62 with PD [6.0%]) of 131 rare variants (minor allele frequency <0.005). A total of 52 patients (48 dystonia [4.0%]; four PD [0.4%, all with GCH1 variants]) carried 33 different (likely) pathogenic variants, of which 17 were not previously reported. Pathogenic biallelic variants in PRKRA were not found. Episignature analysis of 48 KMT2B variants revealed that only two of these should be considered (likely) pathogenic.

CONCLUSION: This study confirms pathogenic variants in GCH1, GNAL, KMT2B, SGCE, THAP1, and TOR1A as relevant causes in dystonia and expands the mutational spectrum. Of note, likely pathogenic variants only in GCH1 were also found among PD patients. For DYT-KMT2B, the recently described episignature served as a reliable readout to determine the functional effect of newly identified variants. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

OriginalspracheEnglisch
ZeitschriftMovement disorders : official journal of the Movement Disorder Society
Jahrgang39
Ausgabenummer3
Seiten (von - bis)526-538
Seitenumfang13
ISSN0885-3185
DOIs
PublikationsstatusVeröffentlicht - 03.2024

Fördermittel

This work was supported by the German Ministry of Education and Research (BMBF, DYSTRACT consortium, 01GM1514B, to A.A.K., T.B., C.Klein and K.L.) and the German Research Foundation (DFG, LO1555/10\u20101 to H.B., C.Klein, and K.L. and Project\u2010ID 424778381\u2010TRR 295 to A.A.K). The DysTract registry was further supported by the Arbeitskreis Botulinumtoxin der DGN e.V., Merz Therapeutics, AbbVie/Allergan, and Ipsen Pharma. The Korean DNA samples for this study were provided by the Seoul National University Hospital Human Biobank, a member of the National Biobank of Korea, which is supported by the Ministry of Health and Welfare. All samples derived from the National Biobank of Korea were obtained with informed consent under institutional review board\u2010approved protocols. Several authors are members of the European Reference Network for Rare Neurological Diseases (Project ID No. 739510). Open Access funding enabled and organized by Projekt DEAL. : This work was supported by the German Ministry of Education and Research (BMBF, DYSTRACT consortium, 01GM1514B, to E.A., A.A.K., T.B., C.Klein, and K.L.) and the Deutsche Forschungsgemeinschaft (DFG FOR 2488, LO1555/10\u20101, LO1555/11\u20101 to H.B., M.K., N.B., C.Klein, and K.L.). Funding agencies

TrägerTrägernummer
Seoul National University Hospital Human Biobank
Deutsche ForschungsgemeinschaftProject‐ID 424778381‐TRR 295, LO1555/10‐1, FOR 2488
Bundesministerium für Bildung und Forschung01GM1514B

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Strategische Forschungsbereiche und Zentren

    • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)
    • Querschnittsbereich: Medizinische Genetik

    DFG-Fachsystematik

    • 2.23-06 Molekulare und zelluläre Neurologie und Neuropathologie

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Zitieren